Stay updated on Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.

Latest updates to the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, and API users can provide input before this change. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.5%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check46 days agoChange DetectedThe webpage has been updated to reflect a new study protocol for ovarian cancer treatments, including the addition of new drugs and the removal of previous treatment details. Key identifiers and collaborators have been retained, indicating a shift in focus towards a revised treatment regimen.SummaryDifference23%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check62 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check91 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.4%
Stay in the know with updates to Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.